Short Interest in Sanofi (NASDAQ:SNY) Declines By 48.7%

Sanofi (NASDAQ:SNY) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 4,530,000 shares, a decline of 48.7% from the November 15th total of 8,830,000 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 2,020,000 shares, the short-interest ratio is presently 2.2 days.

Hedge Funds Weigh In On Sanofi

Several large investors have recently bought and sold shares of the company. Barrow Hanley Mewhinney & Strauss LLC increased its holdings in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the period. Magnetar Financial LLC raised its position in shares of Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after acquiring an additional 2,306,286 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans boosted its holdings in Sanofi by 28,890.2% in the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after acquiring an additional 1,424,289 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SNY shares. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $47.99 on Thursday. The firm has a 50 day moving average of $51.36 and a 200-day moving average of $52.09. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $121.79 billion, a PE ratio of 24.48, a PEG ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.55 EPS. On average, equities research analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.